- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.05. | H.C. Wainwright maintains $50 target on Tourmaline Bio stock | 1 | Investing.com | ||
| 21.05. | Leerink raises Tourmaline Bio target to $54, affirms Outperform | 2 | Investing.com | ||
| 21.05. | Tourmaline Bio stock holds $63 target post-Ph2 data | 3 | Investing.com | ||
| 21.05. | BMO maintains $35 target on Tourmaline Bio, sees overreaction | 1 | Investing.com | ||
| TOURMALINE BIO Aktie jetzt für 0€ handeln | |||||
| 20.05. | Tourmaline Bio shares fall on Phase 2 data; Schrödinger cuts staff | 46 | BioPharma Dive | ||
| 20.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.05. | Tourmaline Bio posts mid-stage data for anti-inflammatory agent | 1 | Seeking Alpha | ||
| 20.05. | Tourmaline Bio, Inc.: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease | 194 | GlobeNewswire (Europe) | - Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo... ► Artikel lesen | |
| 19.05. | Tourmaline Bio wird morgen Ergebnisse der Phase-2-Studie veröffentlichen | 1 | Investing.com Deutsch | ||
| 19.05. | Tourmaline Bio to reveal Phase 2 trial results tomorrow | 1 | Investing.com | ||
| 19.05. | Tourmaline Bio, Inc.: Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 | 2 | GlobeNewswire (USA) | ||
| 02.05. | Talaris Therapeutics GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
| 02.05. | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.05. | Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights | 403 | GlobeNewswire (Europe) | - Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline... ► Artikel lesen | |
| 23.04. | Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock | 1 | Investing.com | ||
| 10.04. | Truist cuts Tourmaline Bio price target to $63, maintains Buy | 2 | Investing.com | ||
| 14.03. | H.C. Wainwright raises Tourmaline Bio stock target to $50 | 3 | Investing.com | ||
| 13.03. | Tourmaline Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
| EVOTEC | 6,778 | +1,35 % | Aktien Frankfurt Ausblick: Leichte Entspannung nach US-Arbeitsmarktschock | FRANKFURT (dpa-AFX) - Nach einem von Konjunktursorgen getriebenen Rückschlag dürfte sich der deutsche Aktienmarkt am Montag zunächst leicht erholen. Der X-Dax signalisierte für den hiesigen Leitindex... ► Artikel lesen | |
| CUREVAC | 4,660 | -0,09 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
| NOVAVAX | 7,220 | +0,36 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| INFLARX | 0,700 | +0,57 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
| CSL | 147,24 | +0,41 % | What to do with your CBA, BHP, and CSL shares now: experts | ||
| COHERUS ONCOLOGY | 0,713 | +0,51 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,450 | -0,24 % | Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data | ||
| CYTOMX THERAPEUTICS | 2,034 | +0,59 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,850 | -1,39 % | Spero Therapeutics, Inc.: Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 | ||
| ORUKA THERAPEUTICS | 12,100 | +8,04 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September | IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 49,600 | -7,29 % | Guggenheim erhöht Kursziel für Cidara Therapeutics nach FDA-Fortschritten | ||
| PALVELLA THERAPEUTICS | 33,000 | -0,60 % | This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | ||
| NEXTCURE | 4,910 | -2,96 % | NextCure GAAP EPS of -$11.29 | ||
| DIANTHUS THERAPEUTICS | 16,400 | -5,75 % | Dianthus Therapeutics GAAP EPS of -$0.88, revenue of $193M |
Das Unternehmen TOURMALINE BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,630 (-2,95 %) liegt der Kurs bei 20,700 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TOURMALINE BIO INC finden Sie auf Wallstreet Online.